Compass (CMPS) Q2 Loss Improves 27%

Compass Pathways Plc (CMPS 10.41%), a clinical-stage mental health company developing psilocybin-based therapies, released its second quarter 2025 results on July 31, 2025. The main headline was a strong clinical update: its lead drug candidate, COMP360 psilocybin, hit its primary goal in a Phase 3 trial for treatment- resistant depression (TRD) with clear statistical and clinical impact. Earnings also slightly exceeded analyst expectations, with a GAAP net loss of $0.41 per share for Q2 2025, better than t ...